Antimicrobial Susceptibility: Reference Range, Interpretation, Collection and Panels
Antimicrobial
Susceptibility Testing Market by Product (Manual {Susceptibility Discs,
Plates, MIC Strips}, Consumables, Automated), Method (Diffusion, Dilution),
Application (Clinical Diagnostics), End User (Hospitals, Pharma, Institutes) -
Forecast to 2028,” published by Meticulous Research®, the antimicrobial
susceptibility testing market is expected to grow at a CAGR of 6.4% from 2021
to 2028 to reach $5.99 billion by 2028.
Download free sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5062?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=21-03-2024
Antimicrobial susceptibility testing (AST) is one of the
vital tasks performed in clinical microbiology laboratories. The primary goal
of these tests is to detect possible drug resistance in common pathogens and
assure susceptibility to drugs of choice for a particular type of infection. In
recent years, the rising antibiotic resistance has led to the increasing demand
for antimicrobial susceptibility testing. The growth of this market is mainly
attributed to the high prevalence of infectious diseases, development of
automated & manual products for AST, increasing government initiatives
& funding towards AST programs, technological advancements towards the
development of new AST methods, and the emergence of multidrug resistance in
microorganisms. Emerging markets and active R&D to develop rapid
antimicrobial susceptibility testing are expected to offer significant growth
opportunities for players operating in the antimicrobial susceptibility testing
market. However, stringent government regulations are expected to hinder the
growth of this market to a certain extent. On the other hand, the high cost of
automated antimicrobial susceptibility testing systems and issues in AMR
surveillance in low-income and middle-income countries pose challenges for the
industry.
The overall antimicrobial susceptibility testing market is
segmented on the basis of product, method, application, end use, and geography.
Based on product, the antimicrobial susceptibility testing
market is segmented into manual AST products, automated AST products, and
consumables. In 2021, the manual AST products segment is estimated to account
for the largest share of the overall antimicrobial susceptibility testing
market. The growth in this market is driven by the inexpensive nature of manual
AST products, simple handling procedures for these products, rising incidence
of antibacterial resistance, availability of a diverse range of consumables for
manual testing, and easy interpretation of these tests.
Based on method, the antimicrobial susceptibility testing
market is segmented into disk diffusion, automated AST, dilution, and other
methods. In 2021, the disk diffusion segment is expected to account for the
largest share of the overall antimicrobial susceptibility testing market. The
advantages of the disk diffusion method are the test simplicity that does not
require any special equipment, the provision of categorical results easily
interpreted by all clinicians, and flexibility in selecting disks for testing.
The low cost of performing AST testing with the disk diffusion methods and
developments in the method with automated technology is primarily boosting the
segment market growth.
Based on application, the antimicrobial susceptibility
testing market is segmented into clinical diagnostics, drug discovery and
development, and other applications. In 2021, the clinical diagnostics segment
is expected to account for the largest share of the global antimicrobial
susceptibility testing market. The large share is mainly attributed to the
rising burden of antibiotic resistance, increasing incidence of HAIs, the
growing procedural volume of clinical diagnostic tests, rising emphasis on effective
and early disease diagnosis across major markets, and growing awareness among
physicians about antimicrobial susceptibility testing methods.
Click here for top trending blog: https://meticulousblog.org/top-10-companies-in-antimicrobial-susceptibility-testing-market/?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=21-03-2024
Based on end user, the antimicrobial susceptibility testing
market is segmented into diagnostic laboratories & hospitals,
pharmaceutical & biotechnology companies, and research & academic
institutes. In 2021, the diagnostic laboratories & hospitals segment is
estimated to account for the largest share of the overall antimicrobial
susceptibility testing market. The large share of this segment is mainly
attributed to the availability of the well-equipped facility and
trained/skilled technicians and rising cases of hospital-acquired infections.
Based on geography, the global antimicrobial susceptibility
testing market is segmented into North America, Europe, Asia-Pacific, Latin
America, and the Middle East & Africa. In 2021, North America is estimated
to account for the largest share of the global antimicrobial susceptibility
testing market, followed by Europe and Asia-Pacific. The large share of the
North American region is attributed to the rising healthcare expenditure,
growing pharmaceutical R&D investment, and availability of advanced susceptibility
testing methods. However, Asia-Pacific is expected to grow at the highest CAGR
of 8.4% due to increasing cases of antibiotic resistance and increasing
awareness about antimicrobial susceptibility testing.
Download request sample report here: https://www.meticulousresearch.com/request-sample-report/cp_id=5062?utm_source=blog&utm_medium=social+&utm_campaign=product&utm_content=21-03-2024
Some of the prominent players operating in the global
antimicrobial susceptibility testing market include Merck KGaA (Germany),
bioMérieux S.A. (France), HiMedia Laboratories Pvt. Ltd. (India), MERLIN
Diagnostika GmbH (Germany), Alifax S.r.l. (Italy), Synbiosis (U.K.), and Zhuhai
DL Biotech Co., Ltd (China) among others. New product launches, enhancements,
approvals, and agreements are some of the key strategies adopted by the players
to expand their service offerings, global footprint and augment their market
share. For instance, in July 2020, the company launched Xpert MTB/XDR, a rapid
molecular test for tuberculosis, and detects resistance to first- and
second-line drugs. Similarly, in October 2019, Becton, Dickinson and Company
(U.S.), along with Check-Points Health B.V. (Netherlands), received FDA 510(k)
clearance for a molecular screening test for antibiotic-resistant carbapenemase
producing organisms (CPOs) on the fully-automated BD MAX System. BD MAX
Check-Points CPO assay provides carbapenemase genes detection directly from
patient samples and improved turn-around time.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment